Given Imaging Ltd. (NASDAQ:GIVN)
The Company develops, manufactures and markets innovative diagnostic products for the visualization and detection of disorders of the gastrointestinal tract.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
bentjeans
(< 20)
Submitted: 1/24/2011 7:06:35 PM :
Start Price:
$17.74
GIVN Score:
-46.82
GIVN has just been approved for an entirely new line of business with PH monitoring. Plus it is near the low of it's 2 year price cycle. As battery life improves the utility of the company's devices continues to increase. Physicians around the world are gradually being exposed to GIVN products.
Recs
mellis2211
(< 20)
Submitted: 8/14/2010 5:17:26 PM :
Start Price:
$13.50
GIVN Score:
-44.46
An Israeli start-up leading the way in bio-imagery using their inventive PillCams.
Recs
Esqangel
(< 20)
Submitted: 5/12/2010 9:46:21 PM :
Start Price:
$14.82
GIVN Score:
-64.97
Given's products are cutting edge
Recs
mdmardim
(< 20)
Submitted: 3/4/2010 9:16:55 PM :
Start Price:
$19.75
GIVN Score:
-72.55
Finds what the scope can't find.
Recs
yeraz
(28.93)
Submitted: 10/11/2008 9:24:44 PM :
Start Price:
$7.54
GIVN Score:
+12.47
Non-invasive medical imaging.
Recs
monikasfantasy
(< 20)
Submitted: 5/2/2008 12:24:06 PM :
Start Price:
$14.98
GIVN Score:
-30.07
GOTTA LOVE THOSE ISREALIES
Recs
Miss57
(51.03)
Submitted: 3/27/2008 8:04:17 PM :
Start Price:
$16.19
GIVN Score:
+39.52
Too much activity with other companies. Isralian have problem with longivity
Recs
CORLEY11
(< 20)
Submitted: 2/21/2008 6:28:59 PM :
Start Price:
$15.21
GIVN Score:
-32.53
AS SOON AS THEY GET APPROVAL FROM THE FDA THIS STOCK SHOULD PERFORM WELL
Recs
SnowWhite418
(< 20)
Submitted: 2/9/2008 4:21:16 PM :
Start Price:
$14.99
GIVN Score:
-32.90
Accelerated growth potential with FDA approval of new products.
Recs
yisroel18
(55.63)
Submitted: 11/1/2007 3:12:14 PM :
Start Price:
$25.38
GIVN Score:
-56.64
the need for this will be on the rise as the baby boomers get of age people are getting sicker
Recs
DoctorsL
(< 20)
Submitted: 7/8/2007 2:09:04 PM :
Start Price:
$28.25
GIVN Score:
-62.39
Esophogeal cancer is, unfortunately, on the rise. The imaging product holds promise. It will take a while to catch on, but it can be viewed as a significant gain for the health sector.
Recs
1Hippydippy
(< 20)
Submitted: 7/4/2007 11:53:02 PM :
Start Price:
$28.96
GIVN Score:
-64.21
no invasive ways to check GI, with the aging population what could be better
Recs
changcellor
(< 20)
Submitted: 7/4/2007 4:37:06 AM :
Start Price:
$28.96
GIVN Score:
-64.21
what i would want if i am having an intestine check
Recs
aubree09876
(< 20)
Submitted: 6/8/2007 4:50:24 PM :
Start Price:
$23.04
GIVN Score:
-52.99
This company is poised to make big profits. The new CEO from Kodak is well-known for his ability to make a company grow, and it is in the next few months that the appointment will pay off.
Recs
kitfine
(< 20)
Submitted: 6/8/2007 11:33:53 AM :
Start Price:
$23.21
GIVN Score:
-54.35
it's ready to turn a profit
Recs
ztur2218
(< 20)
Submitted: 3/12/2007 2:30:54 PM :
Start Price:
$19.18
GIVN Score:
-48.98
great products great company
Recs
tstokesbme
(68.44)
Submitted: 3/4/2007 1:49:29 PM :
Start Price:
$18.37
GIVN Score:
-48.44
My stepmom works for this company. I've also interacted with some of the managers about a technology project for an image processing class. I think the story is solid. I need to find out more about the patent protection before I buy.
Recs
kokit74
(< 20)
Submitted: 2/21/2007 1:11:28 AM :
Start Price:
$20.37
GIVN Score:
+49.47
It's P/E is VERY high considering it's expected growth
Recs
shaiet
(< 20)
Submitted: 12/25/2006 3:04:52 PM :
Start Price:
$18.63
GIVN Score:
-46.94
Great technolgy of a small canera that travel your insides and map tumors. Already approved by FDA, only competition is Olympus.
Recs
irauri
(24.29)
Submitted: 11/23/2006 12:35:19 PM :
Start Price:
$21.12
GIVN Score:
-56.61
Given's PillCam has been gaining traction in the medical community and is gaining acceptance for insurance reimbursement. Stock has been down on fears of increased competition from Olympus but it has a large lead in this area.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 23 : 1 2 Next »